ECL Stock Analysis: Ecolab | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 81.971m USD | 12M Return: 18.1% | US2788651006 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 377M
EPS Trend: 97.7%
Qual. Beats: 0
Rev. Trend: 90.2%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ecolab Inc. (NYSE: ECL) is a U.S.-based provider of water, hygiene, and infection prevention solutions and services, operating across four segments: Global Water, Global Institutional & Specialty, Global Pest Elimination, and Global Life Sciences. Its customer base spans a wide range of industries, including manufacturing, food and beverage, healthcare, hospitality, pharmaceuticals, and primary metals and mining. The company distributes its products through field sales personnel, corporate accounts, distributors, and dealers, and markets them under brands such as Ecolab, Kay, Purolite, and Bioquell.
Founded in 1923 and headquartered in Saint Paul, Minnesota, Ecolab operates within the specialty chemicals subsector of the broader Materials sector. Its business model centers on supplying consumable chemicals, equipment, and service contracts-often on a recurring basis-to commercial and industrial customers, which tends to generate relatively stable, repeat revenue streams tied to customer operating volumes.
- Industrial water treatment demand tracks global manufacturing activity
- Healthcare and foodservice sales lift institutional segment growth
- Raw material and energy costs pressure specialty chemicals margins
| Net Income: 2.08b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.56 > 1.0 |
| NWC/Revenue: 4.15% < 20% (prev 18.37%; Δ -14.22% < -1%) |
| CFO/TA 0.10 > 3% & CFO 3.06b > Net Income 2.08b |
| Net Debt (13.8b) to EBITDA (3.65b): 3.78 < 3 |
| Current Ratio: 1.11 > 1.5 & < 3 |
| Outstanding Shares: last quarter (282.1m) vs 12m ago -1.16% < -2% |
| Gross Margin: 43.94% > 18% (prev 44.32%; Δ -0.38% > 0.5%) |
| Asset Turnover: 63.17% > 50% (prev 66.49%; Δ -3.33% > 0%) |
| Interest Coverage Ratio: 8.42 > 6 (EBIT TTM 2.98b / Interest Expense TTM 353.5m) |
| A: 0.02 (Total Current Assets 7.10b - Total Current Liabilities 6.38b) / Total Assets 31.1b |
| B: 0.44 (Retained Earnings 13.7b / Total Assets 31.1b) |
| C: 0.11 (EBIT TTM 2.98b / Avg Total Assets 27.5b) |
| D: 0.50 (Book Value of Equity 10.4b / Total Liabilities 20.7b) |
| Altman-Z'' = 2.85 = A |
| DSRI: 1.05 (Receivables 3.80b/3.32b, Revenue 17.4b/15.9b) |
| GMI: 1.01 (GM 44.32% / 43.94%) |
| AQI: 1.20 (AQ_t 0.60 / AQ_t-1 0.50) |
| SGI: 1.09 (Revenue 17.4b / 15.9b) |
| TATA: -0.03 (NI 2.08b - CFO 3.06b) / TA 31.1b) |
| Beneish M = -2.80 (Cap -4..+1) = A |
As of October 30, 2026, the stock is trading at USD 300.86 with a total of 2,033,968 shares traded. Over the past week, the price has changed by +2.93%, over one month by +8.27%, over three months by +6.33% and over the past year by +18.13%.
Current recommended Stop Loss: 293.30 (which is 2.5% or 1.3 ATR below the current price).
Ecolab has received a consensus analysts rating of 4.46. Therefore, it is recommended to buy ECL.
- StrongBuy: 15
- Buy: 5
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 329 | 9.4% |
P/E Trailing = 39.9467
P/E Forward = 31.25
P/S = 4.7185
P/B = 7.8331
P/EG = 2.6248
Revenue TTM = 17.4b USD
EBIT TTM = 2.98b USD
EBITDA TTM = 3.65b USD
Long Term Debt = 7.37b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.28b USD (from shortTermDebt, last quarter)
Debt = 14.5b USD (from shortLongTermDebtTotal, last quarter) + Leases 742.6m
Net Debt = 13.8b USD (calculated: Debt 14.5b - CCE 722.3m)
Enterprise Value = 95.8b USD (82.0b + Debt 14.5b - CCE 722.3m)
Interest Coverage Ratio = 8.42 (Ebit TTM 2.98b / Interest Expense TTM 353.5m)
EV/FCF = 51.09x (Enterprise Value 95.8b / FCF TTM 1.87b)
FCF Yield = 1.96% (FCF TTM 1.87b / Enterprise Value 95.8b)
FCF Margin = 10.79% (FCF TTM 1.87b / Revenue TTM 17.4b)
Net Margin = 11.99% (Net Income TTM 2.08b / Revenue TTM 17.4b)
Gross Margin = 43.94% ((Revenue TTM 17.4b - Cost of Revenue TTM 9.74b) / Revenue TTM)
Gross Margin QoQ = 44.08% (prev 44.07%)
Tobins Q-Ratio = 3.08 (Enterprise Value 95.8b / Total Assets 31.1b)
Interest Expense / Debt = 2.44% (Interest Expense 353.5m / Debt 14.5b)
Taxrate = 19.50% (508.2m / 2.61b)
NOPAT = 2.40b (EBIT 2.98b * (1 - 19.50%))
Current Ratio = 1.11 (Total Current Assets 7.10b / Total Current Liabilities 6.38b)
Debt / Equity = 1.39 (Debt 14.5b / totalStockholderEquity, last quarter 10.4b)
Debt / EBITDA = 3.78 (Net Debt 13.8b / EBITDA 3.65b)
Debt / FCF = 7.36 (Net Debt 13.8b / FCF TTM 1.87b)
Total Stockholder Equity = 10.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.57% (Net Income 2.08b / Total Assets 31.1b)
RoE = 20.70% (Net Income TTM 2.08b / Total Stockholder Equity 10.1b)
RoCE = 17.08% (EBIT 2.98b / Capital Employed (Equity 10.1b + L.T.Debt 7.37b))
RoIC = 9.48% (NOPAT 2.40b / Invested Capital 25.3b)
WACC = 6.16% (E(82.0b)/V(96.5b) * Re(6.90%) + D(14.5b)/V(96.5b) * Rd(2.44%) * (1-Tc(0.19)))
Discount Rate = 6.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -96.12 | Cagr: -0.76%
[DCF] Terminal Value 77.97% ; FCFF base≈1.75b ; Y1≈2.01b ; Y5≈2.96b
[DCF] Fair Price = 109.7 (EV 44.5b - Net Debt 13.8b = Equity 30.7b / Shares 280.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 97.75 | EPS CAGR: 15.96% | SUE: 0.0 | # QB: 0
Revenue Correlation: 90.17 | Revenue CAGR: 3.77% | SUE: -0.19 | # QB: 0
EPS current Quarter (2027-03-31): EPS=1.88 | Chg30d=-1.27% | Revisions=-25% | Analysts=11
EPS current Year (2026-12-31): EPS=8.16 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+8.4% | GrowthRev=+11.5%
EPS next Year (2027-12-31): EPS=9.39 | Chg30d=-0.06% | Revisions=-29% | GrowthEPS=+15.1% | GrowthRev=+7.9%
[Analyst] Revisions Ratio: -25% (up=3, down=6)